Exhibit 99.1 QIAGEN N.V. and Subsidiaries U.S. GAAP Quarterly Report for the Period Ended September 30, 2025 Table of Contents Condensed Consolidated Financial Statements 2 Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 4 Condensed Consolidated Statements of Income (Loss) (unaudited) for the three and nine months ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended Septe ...

Financial Data and Key Metrics Changes - Net sales increased by 6% to $533 million, with core sales (excluding discontinued products) also rising by 6% at constant exchange rates [5][10][12] - Adjusted diluted EPS was $0.61, exceeding the outlook of at least $0.58 [8][16] - Adjusted operating income margin remained steady at 29.6% of sales, with cash generation strong at $466 million for the first nine months of 2025 [10][11][16] Business Line Data and Key Metrics Changes - QuantiFERON grew by 11%, driven by strong instrument placements and consumable demand [6][12] - Sample technologies returned to growth with a 3% increase in sales, while QIAcuity maintained double-digit growth [7][12] - QIAGEN Digital Insights delivered solid double-digit growth, supported by the integration of Genox [7][12] Market Data and Key Metrics Changes - Sales in the Americas rose by 7% at constant exchange rates, while EMEA grew by 4% [14] - The Asia-Pacific region saw a decline of 2%, primarily due to a mid-teens decline in China [14] Company Strategy and Development Direction - The company announced the acquisition of PARS Biosciences to expand into the AI-driven single-cell market, enhancing its sample technologies portfolio [5][22] - A $500 million synthetic share repurchase program was announced, aiming to return over $1 billion to shareholders by 2028 [5][11] - The company remains committed to achieving a 7% sales CAGR from 2024 to 2028 and aims to exceed a 31% adjusted operating income margin by the end of 2028 [5][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the challenging macro environment while maintaining solid growth [4][8] - The adjusted EPS target for 2025 was raised to about $2.38, reflecting improved profitability despite currency headwinds [8][25] - The company anticipates continued growth in core sales and expects to mitigate the impact of tariffs and the U.S. government shutdown [8][41] Other Important Information - The company is on track to launch new sample prep instruments and expand its syndromic testing portfolio [19][23] - R&D investments increased to 9.2% of sales, focusing on key growth pillars [15][16] - The company is preparing for a leadership transition, with the current CEO planning to step down after more than 10 years [9] Q&A Session Summary Question: Can you discuss the PARS acquisition and its competitive landscape? - The acquisition of PARS is strategic and synergistic, allowing QIAGEN to enter the fast-growing single-cell analysis market with instrument-free technology that processes millions of cells [30][32] Question: What is the traction for the new panels in syndromic testing? - QIAGEN Sack continues to deliver strong growth, particularly in GI and meningitis panels, with expectations to exceed midterm revenue guidance [34][36] Question: How have the new panels contributed to platform growth? - The three key panels have significantly contributed to U.S. performance, with more instruments placed in the first half of 2025 than in the entire previous year [37] Question: What is the impact of the U.S. government shutdown on sales? - The shutdown is expected to impact sales, particularly in academia and research, but the company has maintained its guidance for the year [41][43] Question: Can you elaborate on the tariff impact on margins? - The company expects a 90 basis point impact from tariffs, which is net of mitigation efforts, and does not anticipate a larger impact for the next year [45][46] Question: What are the expectations for 2026? - The company is positioned for growth between 5-7% in 2026, depending on market conditions, while maintaining a focus on profitability and cash generation [50][53]

Financial Performance - Core sales increased by 6% CER to $532 million, exceeding the outlook of ≥5%[5,9] - Net sales reached $533 million, a 5% CER increase compared to Q3 2024[5,7] - Adjusted diluted EPS was $0.61 CER, a 7% CER increase, surpassing the outlook of ≥$0.58 CER[5] - Adjusted operating income margin remained steady at 29.6%[5,24] - Operating cash flow for 9M 2025 was $466 million, a 3% decrease[5] Product and Portfolio Developments - QIAstat-Dx and QuantiFERON both experienced 11% CER growth, leading the portfolio[5,8] - Sample technologies showed a 3% CER growth[5,8] - QIAcuity digital PCR and QDI delivered solid contributions[5,8] - Parse Biosciences acquisition is expected to contribute ~$40 million in sales in 2026[22] Outlook and Capital Allocation - The company reaffirmed its 2025 net sales outlook of +4-5% CER (+5-6% CER core growth)[5] - The company increased its adjusted diluted EPS outlook to ~$2.38 CER (previously ~$2.35 CER)[5] - At least $1 billion of returns to shareholders is planned for 2024-28 (absent M&A)[14] - $500 million share repurchase program is authorized for completion in January 2026[15]

Core Insights - Qiagen reported revenue of $532.58 million for Q3 2025, a year-over-year increase of 6.1%, with an EPS of $0.61 compared to $0.59 a year ago, exceeding the Zacks Consensus Estimate of $525.99 million by 1.25% [1] - The company delivered an EPS surprise of 5.17%, with the consensus EPS estimate being $0.58 [1] Financial Performance - Qiagen's stock has returned -2.7% over the past month, while the Zacks S&P 500 composite increased by 2.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3] Sales by Product Groups - Diagnostic solutions - QIAstat-Dx: $32 million vs. $34.77 million estimated, +14.3% year-over-year [4] - Diagnostic solutions - QuantiFERON: $136 million vs. $133.3 million estimated, +11.5% year-over-year [4] - Diagnostic solutions - Other: $41 million vs. $39.24 million estimated, 0% year-over-year [4] - Other: $18 million vs. $17.37 million estimated, +28.6% year-over-year [4] - PCR / Nucleic acid amplification: $75 million vs. $76.5 million estimated, +1.4% year-over-year [4] - Genomics / NGS: $61 million vs. $60.62 million estimated, +10.9% year-over-year [4] - Diagnostic solutions total: $209 million vs. $207.61 million estimated, +6.1% year-over-year [4] - Sample technologies: $170 million vs. $163.77 million estimated, +4.9% year-over-year [4]

分组1 - Qiagen reported quarterly earnings of $0.61 per share, exceeding the Zacks Consensus Estimate of $0.58 per share, and showing an increase from $0.59 per share a year ago, resulting in an earnings surprise of +5.17% [1] - The company achieved revenues of $532.58 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.25% and increasing from $501.87 million year-over-year [2] - Over the last four quarters, Qiagen has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] 分组2 - The stock has underperformed the market, losing about 0.3% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is $0.60 on revenues of $542.45 million, and for the current fiscal year, it is $2.34 on revenues of $2.09 billion [7] - The Medical - Biomedical and Genetics industry, to which Qiagen belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Insights - QIAGEN N.V. announced its third quarter 2025 results and reaffirmed its outlook for solid profitable growth while raising profitability targets [1] - The company expects net sales growth of approximately 4-5% CER for FY 2025, with core sales growth (excluding divestments) projected at about 5-6% CER [1] - QIAGEN raised its adjusted diluted EPS target to approximately $2.38 CER, up from the previous target of about $2.35 CER [1] Financial Performance - QIAGEN's third quarter results indicate a strong performance, contributing to the positive outlook for the remainder of FY 2025 [1] - The adjusted operating performance is expected to align with the raised profitability targets, reflecting the company's commitment to growth [1]

Core Insights - QIAGEN has announced a definitive agreement to fully acquire Parse Biosciences, enhancing its capabilities in single-cell research solutions [1] - This acquisition will significantly expand QIAGEN's Sample technologies portfolio into the rapidly growing single-cell sequencing market [1] - The technology from Parse Biosciences is designed to support research involving up to millions of cells, indicating a strong scalability potential [1]

Core Insights - QIAGEN has achieved the milestone of 4,000 placements of its QIAcube Connect instrument, indicating strong adoption of automation in sample processing across life science and diagnostic labs [1] - The company has a total of nearly 13,000 cumulative placements of QIAcube platforms globally and over 29,900 placements of QIAGEN Sample technology instruments since 2019, showcasing widespread trust in its products [2] Product Features - QIAcube is designed to facilitate the transition from manual to automated workflows without the need for revalidation of protocols, enhancing efficiency and standardization in laboratories [3] - The QIAcube Connect supports over 80 QIAGEN kits and more than 140 standard protocols, with the capability to customize protocols exceeding 3,000, incorporating features like remote monitoring and automated decontamination [4] Market Position and Future Plans - QIAGEN's investment in automation is driven by customer demand for speed, reliability, and standardization, with plans to launch three new automation systems in 2025 and 2026 to further strengthen its market leadership [5][6] - The upcoming products include QIAsymphony Connect, QIAsprint, and QIAmini, each designed to cater to different laboratory scales and needs, enhancing QIAGEN's comprehensive automation portfolio [9]

Core Viewpoint - Qiagen (QGEN) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended September 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate for Qiagen's quarterly earnings is $0.58 per share, reflecting a year-over-year decrease of 1.7%, while revenues are projected to be $525.99 million, representing a 4.8% increase from the previous year [3]. - The earnings report is scheduled for release on November 4, and the stock may experience upward movement if the reported figures exceed expectations, whereas a miss could lead to a decline [2]. Estimate Revisions - Over the past 30 days, the consensus EPS estimate has been revised down by 0.67%, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Qiagen is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.73%, which complicates the prediction of an earnings beat [12]. Earnings Surprise History - In the last reported quarter, Qiagen met the expected earnings of $0.60 per share, resulting in no surprise [13]. - Over the last four quarters, the company has surpassed consensus EPS estimates in two instances [14]. Industry Context - Syndax Pharmaceuticals (SNDX), a peer in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $0.74 per share for the same quarter, marking a year-over-year change of +24.5%, with revenues projected at $48.69 million, up 289.5% from the previous year [18]. - Despite a recent downward revision of 13.9% in the consensus EPS estimate for Syndax, it currently holds an Earnings ESP of +0.23%, although it has a Zacks Rank of 4 (Sell), making predictions of an earnings beat challenging [19][20].

Core Insights - Qiagen (QGEN) is currently more attractive to value investors compared to Acadia Pharmaceuticals (ACAD) based on various financial metrics and rankings [1][3][7] Valuation Metrics - QGEN has a forward P/E ratio of 20.42, significantly lower than ACAD's forward P/E of 40.72, indicating that QGEN may be undervalued [5] - The PEG ratio for QGEN is 2.52, while ACAD's PEG ratio is much higher at 7.49, suggesting QGEN offers better value relative to its expected earnings growth [5] - QGEN's P/B ratio stands at 3.03 compared to ACAD's 4.37, further supporting the notion that QGEN is a more attractive investment [6] Zacks Rank and Value Grades - QGEN holds a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook compared to ACAD, which has a Zacks Rank of 3 (Hold) [3][7] - Based on the valuation metrics, QGEN has earned a Value grade of B, while ACAD has a Value grade of C, reinforcing QGEN's position as the superior value option [6]